The Giroir FDA: Acting Tenure Ending Soon – But It Was Eventful
Executive Summary
Brett Giroir’s tenure as acting commissioner of the US FDA won’t last long, but it has marked another high water mark in the pro-innovation climate at the agency, which is an important message about what FDA commissioners do – and don’t – actually do.
You may also be interested in...
Keeping Track: Vascepa Adds CV Risk Reduction Claim And Submissions Pour Into FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
New US FDA Commissioner Stephen Hahn Heads to White Oak Under Vaping Cloud
Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.